PURPOSE: We undertook this study to determine (1) the frequency with which spilled tumor cells of favorable histology produced intra-abdominal disease in patients treated with differingchemotherapy regimens and abdominal radiation therapy (RT) and (2) the patterns of relapse and outcomes in such patients. METHODS AND MATERIALS: The influence of RT dose (0, 10, and 20 Gy), RT fields (flank, whole abdomen), and chemotherapy with dactinomycin and vincristine (2 drugs) vs. added doxorubicin (three drugs) on intra-abdominal tumor recurrence rates was analyzed by logistic regression in 450 patients. Each patient was considered at risk for two types of failure: flank and subdiaphragmatic beyond-flank recurrence, with the correlation between the two outcomes accounted for in the analyses. RESULTS: The crude odds ratio for the risk of recurrence relative to no RT was 0.35 (0.15-0.78) for 10Gy and 0.08 (0.01-0.58) for 20Gy. The odds ratio for the risk of recurrence for doxorubicin to two drugs after adjusting for RT was not significant. For Stage II patients (NWTS-4), the 8-year event rates with and without spillage, respectively, were 79% and 87% for relapse-free survival (p = 0.07) and 90% and 95% for overall survival (p = 0.04). CONCLUSIONS: Irradiation (10 Gy or 20 Gy) reduced abdominal tumor recurrence rates after tumor spillage. Tumor spillage in Stage II patients reduced relapse-free survival and overall survival, but only the latter was of statistical significance. These data provide a basis for assessing the risks vs. benefits when considering treatment for children with favorable histology Wilms tumor and surgical spillage.
RCT Entities:
PURPOSE: We undertook this study to determine (1) the frequency with which spilled tumor cells of favorable histology produced intra-abdominal disease in patients treated with differing chemotherapy regimens and abdominal radiation therapy (RT) and (2) the patterns of relapse and outcomes in such patients. METHODS AND MATERIALS: The influence of RT dose (0, 10, and 20 Gy), RT fields (flank, whole abdomen), and chemotherapy with dactinomycin and vincristine (2 drugs) vs. added doxorubicin (three drugs) on intra-abdominal tumor recurrence rates was analyzed by logistic regression in 450 patients. Each patient was considered at risk for two types of failure: flank and subdiaphragmatic beyond-flank recurrence, with the correlation between the two outcomes accounted for in the analyses. RESULTS: The crude odds ratio for the risk of recurrence relative to no RT was 0.35 (0.15-0.78) for 10Gy and 0.08 (0.01-0.58) for 20Gy. The odds ratio for the risk of recurrence for doxorubicin to two drugs after adjusting for RT was not significant. For Stage II patients (NWTS-4), the 8-year event rates with and without spillage, respectively, were 79% and 87% for relapse-free survival (p = 0.07) and 90% and 95% for overall survival (p = 0.04). CONCLUSIONS: Irradiation (10 Gy or 20 Gy) reduced abdominal tumor recurrence rates after tumor spillage. Tumor spillage in Stage II patients reduced relapse-free survival and overall survival, but only the latter was of statistical significance. These data provide a basis for assessing the risks vs. benefits when considering treatment for children with favorable histology Wilms tumor and surgical spillage.
Authors: D M Green; N E Breslow; J B Beckwith; J Z Finklestein; P E Grundy; P R Thomas; T Kim; S J Shochat; G M Haase; M L Ritchey; P P Kelalis; G J D'Angio Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: Daniel M Green; Eve M Peabody; Bin Nan; Susan Peterson; John A Kalapurakal; Norman E Breslow Journal: J Clin Oncol Date: 2002-05-15 Impact factor: 44.544
Authors: D M Green; Y A Grigoriev; B Nan; J R Takashima; P A Norkool; G J D'Angio; N E Breslow Journal: J Clin Oncol Date: 2001-04-01 Impact factor: 44.544
Authors: R C Shamberger; K A Guthrie; M L Ritchey; G M Haase; J Takashima; J B Beckwith; G J D'Angio; D M Green; N E Breslow Journal: Ann Surg Date: 1999-02 Impact factor: 12.969
Authors: Daniel M Green; Cecilia A Cotton; Marcio Malogolowkin; Norman E Breslow; Elizabeth Perlman; James Miser; Michael L Ritchey; Patrick R M Thomas; Paul E Grundy; Giulio J D'Angio; J Bruce Beckwith; Robert C Shamberger; Gerald M Haase; Milton Donaldson; Robert Weetman; Max J Coppes; Patricia Shearer; Peter Coccia; Morris Kletzel; Roger Macklis; Gail Tomlinson; Vicki Huff; Robert Newbury; Douglas Weeks Journal: Pediatr Blood Cancer Date: 2007-05 Impact factor: 3.167
Authors: Norman E Breslow; J Bruce Beckwith; Gerald M Haase; John A Kalapurakal; Michael L Ritchey; Robert C Shamberger; Patrick R M Thomas; Giulio J D'Angio; Daniel M Green Journal: Int J Radiat Oncol Biol Phys Date: 2006-03-20 Impact factor: 7.038
Authors: John A Kalapurakal; Sierra M Li; Norman E Breslow; J Bruce Beckwith; Roger Macklis; Patrick R M Thomas; Guilio J D'Angio; Tae Kim; Alfred de Lorimier; Panayotis Kelalis; Steven Shochat; Michael Ritchey; Gerald Haase; Ellen Hrabovsky; H Biemann Otherson; Paul Grundy; Daniel M Green Journal: Int J Radiat Oncol Biol Phys Date: 2003-10-01 Impact factor: 7.038
Authors: Daniel M Green; Norman E Breslow; Giulio J D'Angio; Marcio H Malogolowkin; Michael L Ritchey; Audrey E Evans; J Bruce Beckwith; Elizabeth J Perlman; Robert C Shamberger; Susan Peterson; Paul E Grundy; Jeffrey S Dome; Patrick R M Thomas; John A Kalapurakal Journal: Pediatr Blood Cancer Date: 2013-08-23 Impact factor: 3.167
Authors: Ossama M Zakaria; Emad N Hokkam; Karam Al Sayem; Mohamed Yasser I Daoud; Hazem M Zakaria; Fouad Sedky; Seba H Graiz; Saleh A Moussa; Hamed A Al Wadaani Journal: World J Oncol Date: 2015-10-26